Title: Clinical observation on sitagliptin combined BIAsp30 in the treatment of type 2 diabetes
Abstract: OBJECTIVE To explore the effect and safety of combination of sitagliptin and BIAsp30 in the treatment of patients with type2 diabetes.METHODS 80 cases of type 2 diabetes patients who had inefficacious treatment with long history of taking oral hypoglycemic drugs were selected.Totally 80 patients were randomly divided into experimental group and control group.Experimental group received sitagliptin combined BIAsp30 treatment for 16 weeks,and control group received BIAsp30 therapy.Fasting blood glucose(FBG),2h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c),insulin dose and BMI of two groups were measured on week 0,8,and 16 respectively.C peptide levels were also detected on week 16.RESULTS FBG,2hPG,HbA1c of two groups decreased significantly on week 8 and 16(P0.05).Compared with control group,FBG,2hPG,HbA1c of experimental group decreased significantly(P0.05).After 16 weeks,the insulin dose and BMI of experimental group were much lower than those of control group(P0.05),but C peptide levels of experimental group were much higher than those of control group(P0.05).CONCLUSION Combination of sitagliptin and BIAsp30 can significantly decrease blood glucose,improve insulin function,reduce weight gain and hypoglycemia episodes,which indicate it is a safe and effective therapy strategy for patients with type 2 diabetes.
Publication Year: 2013
Publication Date: 2013-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot